Camp4 Therapeutics (CAMP) Cash & Equivalents (2023 - 2026)

Camp4 Therapeutics (CAMP) has 4 years of Cash & Equivalents data on file, last reported at $99.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 101.24% year-over-year to $99.2 million; the trailing twelve-month figure through Mar 2026 stood at $99.2 million (up 101.24% YoY), and the FY2025 full-year result was $109.5 million, up 71.02% from the prior year.
• Cash & Equivalents declined to $99.2 million in Q1 2026, from $109.5 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $109.5 million in Q4 2025 to a low of $2.5 million in Q3 2024.
• A 4-year average of $58.6 million and a median of $50.5 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents plunged 94.99% in 2024 and soared 2876.86% in 2025, its largest moves.
• Tracing CAMP's Cash & Equivalents over 4 years: stood at $38.4 million in 2023, then jumped by 66.86% to $64.0 million in 2024, then soared by 71.02% to $109.5 million in 2025, then declined by 9.41% to $99.2 million in 2026.
• Business Quant data shows CAMP's Cash & Equivalents at $99.2 million in Q1 2026, $109.5 million in Q4 2025, and $75.3 million in Q3 2025.